Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice

Pharmacological Research

Volumn 64, Issue 5, 2011, Pages 482-492

  Cozzoli, Anna ^a   Nico, Beatrice ^a   Sblendorio, Valeriana Teresa ^a   Capogrosso, Roberta Francesca ^a   Dinardo, Maria Maddalena ^a   Longo, Vito ^a   Gagliardi, Sara ^a   Montagnani, Monica ^a   De Luca, Annamaria ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Angiotensin II; Inflammation; Muscular dystrophy; Oxidative stress; Pre clinical pharmacological tests

Indexed keywords

ANGIOTENSIN II; ENALAPRIL; HYDROETHIDINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLPREDNISOLONE; SMAD2 PROTEIN; SMAD3 PROTEIN; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CALCIUM HOMEOSTASIS; CHLORIDE CONDUCTANCE; CONTROLLED STUDY; DIAPHRAGM; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; FORELIMB; GASTROCNEMIUS MUSCLE; HISTOPATHOLOGY; INFLAMMATION; MALE; MICROELECTRODE; MOUSE; MUSCLE NECROSIS; MUSCLE STRENGTH; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; TIBIALIS ANTERIOR MUSCLE;

EID: 80054989179     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.06.002     Document Type: Article

References (44)

1. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 2008;31:1-19.
2. Willmann R, Possekel S, Dubach-Powell J, Meier T, Ruegg MA. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 2009;19:241-9.
3. Hoffman EP, Dressman D. Molecular pathophysiology and targeted therapeutics for muscular dystrophy. Trends Pharmacol Sci 2001;22:465-70. (Pubitemid 32816939)
4. Rando TA, Disatnik MH, Yu Y, Franco A. Muscle cells from mdx mice have an increased susceptibility to oxidative stress. Neuromuscul Disord 1998;8:14-21. (Pubitemid 28174930)
5. Whitehead NP, Yeung EW, Allen DG. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006;33:657-62. (Pubitemid 43894030)
6. Bushby K, Straub V. Nonmolecular treatment for muscular dystrophies. Curr Opin Neurol 2005;18:511-8. (Pubitemid 41476136)
7. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
8. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Bécane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45:855-7. (Pubitemid 40342808)
9. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007;154:596-602. (Pubitemid 47268252)
10. Bauer R, Straub V, Blain A, Bushby K, MacGowan GA. Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail 2009;11:463-71.
11. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, et al. type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007;13:204-10.
12. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007;117:568-75. (Pubitemid 46348511)
13. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210. (Pubitemid 351160157)
14. Martin MM, Buckenberger JA, Jiang J, Malana GE, Knoell DL, Feldman DS, et al. TGF-beta1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. Am J Physiol Lung Cell Mol Physiol 2007;293:L790-9. (Pubitemid 47358842)
15. Gazzerro E, Assereto S, Bonetto A, Sotgia F, Scarfì S, Pistorio A, et al. Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol 2010;176:1863-77.
16. Russell ST, Wyke SM, Tisdale MJ. Mechanism of induction of muscle protein degradation by angiotensin II. Cell Signal 2006;18:1087-96.
17. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2008;294: E345-351.
18. Arthur PG, Grounds MD, Shavlakadze T. Oxidative stress as a therapeutic target during muscle wasting: considering the complex interactions. Curr Opin Clin Nutr Metab Care 2008;11:408-16.
19. Burdi R, Rolland JF, Fraysse B, Litvinova K, Cozzoli A, Giannuzzi V, et al. Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. J Appl Physiol 2009;106:1311-24.
20. Shkryl VM, Martins AS, Ullrich ND, Nowycky MC, Niggli E, Shirokova N. Reciprocal amplification of ROS and Ca(2+) signals in stressed mdx dystrophic skeletal muscle fibers. Pflugers Arch 2009;458:915-28.
21. Spurney CF, Knoblach S, Pistilli EE, Nagaraju K, Martin GR, Hoffman EP. Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord 2008;18:371-81.
22. Williams IA, Allen DG. The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 2007;293:H1969-1977. (Pubitemid 47367249)
23. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007;117:889-901. (Pubitemid 46556745)
24. Messina S, Altavilla D, Aguennouz M, Seminara P, Minutoli L, Monici MC, et al. Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 2006;168:918-26. (Pubitemid 43327744)
25. Wang P, Fedoruk MN, Rupert JL. Keeping pace with ACE: are ACE inhibitors and angiotensin II type 1 receptor antagonists potential doping agents? Sports Med 2008;38:1065-79.
26. De Luca A, Nico B, Liantonio A, Didonna MP, Fraysse B, Pierno S, et al. A multidisciplinary evaluation of the effectiveness of cyclosporine A in dystrophic mdx mice. Am J Pathol 2005;166:477-89. (Pubitemid 40189044)
27. Cozzoli A, Rolland JF, Capogrosso RF, Sblendorio VT, Longo V, Simonetti S, et al. Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy. Neuropathol Appl Neurobiol 2011;37: 243-56.
28. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 2003;304:453-63. (Pubitemid 36008959)
29. De Luca A, Nico B, Rolland JF, Cozzoli A, Burdi R, Mangieri D, et al. Gentamicin treatment in exercised mdx mice: identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol Dis 2008;32:243-53.
30. Ortiz LA, Champion HC, Lasky JA, Gambelli F, Gozal E, Hoyle GW, et al. Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol 2002;282:L1209-21. (Pubitemid 34654576)
31. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61. (Pubitemid 351348146)
32. Simolin MA, Pedersen TX, Bro S, Mäyränpää MI, Helske S, Nielsen LB, et al. ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model. BMC Cardiovasc Disord 2009;3:9-10.
33. Pierno S, Nico B, Burdi R, Liantonio A, Didonna MP, Cippone V, et al. Role of TNFalpha, but not of COX-2 derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol Appl Neurobiol 2007;33:344-59. (Pubitemid 46701042)
34. Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 2008;456:511-5. (Pubitemid 352759004)
35. Cozzoli A, Pierno S, Conte Camerino D, De Luca A. Skeletal muscle chloride channel, a biophysical sensor of dystrophic progression in mdx mouse, is a potential target of pro-inflammatory mediators. Biophys J 2009;96:469a-70a.
36. Rolland JF, De Luca A, Burdi R, Andreetta F, Confalonieri P, Conte Camerino D. Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: beneficial effect of pentoxifylline. Neurobiol Dis 2006;24:466-74. (Pubitemid 44716676)
37. Sun G, Haginoya K, Dai H, Chiba Y, Uematsu M, Hino-Fukuyo N, et al. Intramuscular renin-angiotensin system is activated in human muscular dystrophy. J Neurol Sci 2009;280:40-8.
38. Johnston AP, Baker J, De Lisio M, Parise G. Skeletal muscle myoblasts possess a stretch-responsive local angiotensin signalling system. J Renin Angiotensin Aldosterone Syst 2010 [Epub ahead of print].
39. Yoshida T, Semprun-Prieto L, Sukhanov S, Delafontaine P. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol 2010;298:H1565-1570.
40. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002;91:406-13. (Pubitemid 35034208)
41. White CN, Figtree GA, Liu CC, Garcia A, Hamilton EJ, Chia KK, et al. Angiotensin II inhibits the Na+-K+ pump via PKC-dependent activation of NADPH oxidase. Am J Physiol Cell Physiol 2009;296:C693-700.
42. Semprun-Prieto LC, Sukhanov S, Yoshida T, Rezk BM, Gonzalez-Villalobos RA, Vaughn C, et al. Angiotensin II induced catabolic effect and muscle atrophy are redox dependent. Biochem Biophys Res Commun 2011. May 6 [Epub ahead of print].
43. Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 2011;3(82):ra37.
44. Lanz TV, Ding Z, Ho PP, Luo J, Agrawal AN, Srinagesh H, et al. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest 2010;120: 2782-94.